title: [Anesthesia and postoperative care of 11 patients undergoing peritonectomy and hypothermic intraperitoneal chemotherapy].
abstract: Peritoneal carcinomatosis is the final stage of certain malignant tumors located both inside and outside the abdomen. Mortality is high with conventional treatments and the best mean survival rates reported have reached up to 6 months. One technique tried in recent years involves resection of macroscopic parietal and visceral peritoneal lesions (peritonectomy) combined with intra- and postoperative perfusion of the abdominal cavity with hyperthermic chemotherapy to treat residual microscopic lesions. Five-year survival in series so-treated can reach as high as 80%, depending on tumor histology. Anesthetic management in these patients is complex, particularly because of the aggressive nature of the procedure. The main complications are related to the long duration of surgery, bleeding secondary to the many surgical resections, and hyperthermia caused by the chemical agents. The therapeutic process, therefore, is not risk-free and involves high rates of morbidity and mortality. We describe the anesthetic and postoperative management of the first 11 cases in which this procedure was carried out at our hospital, analyzing the main complications arising.
authors.affiliation: Servicio de Anestesiología y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid. jllberlanga@terra.es
authors.forename: J L
authors.initials: JL
authors.lastname: López-Berlanga
authors.forename: A
authors.initials: A
authors.lastname: De Miguel
authors.forename: A
authors.initials: A
authors.lastname: Elvira
mesh_terms: D000328:Adult; D000758:Anesthesia; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D010534:Peritoneal Neoplasms / Q000628:therapy*; D010537:Peritoneum / Q000601:surgery*; D011182:Postoperative Care
chemical_list: D000970:Antineoplastic Agents